Acta Med. 2003, 46: 3-7
https://doi.org/10.14712/18059694.2019.1
Extracorporeal LDL-Cholesterol Elimination in the Treatment of Severe Familial Hypercholesterolemia
References
1. Agashi T, Kaneko J, Hasuo Y et al. Double filtration plasmapheresis with no or minimal amount of blood derivative for substitution. In: Sieberth HG, eds. Plasma exchange, Plasmapheresis – plasmaseparation. New York, Stuttgart: Schattauer, 1980: 53–7.
2. Antwiler GD, Dau PC, Lobdell DD Treatment of familial hypercholesterolemia by precipitation of low density lipoproteins with dextransulfate. Manuscript. After Borberg, H. LDL-Apheresis and LDL-Elimination Therapies. In: European School of Haematology, eds. 2nd Seminar of Applied Technology in Haemapheresis (Proceedings), Paris: ESH 1997:1–8.
3. R, Scheil R, Latza R. Current topics on low-density lipoprotein apheresis. Ther Apher 2001; 5:93–300.
4. V, Zadák Z, Bláha M, Havel E, Vyroubal P, Malý J. Klinické využití imunoadsorpční LDL-aferézy v léčbě hypercholesterolémií. Diabetol Metabol Endokrinol Výživa 2001; 4(Suppl. 4): 36.
5. V, Zadák Z, Bláha M et al. Selekční kritéria k léčbě závažných hyperlipoproteinémií metodou LDL-aferéz. Cas Lek ces 1998; 137:424–9.
6. Borberg H LDL-Apheresis and LDL-Elimination Therapies. In: European School of Haematology, eds. 2nd Seminar of Applied Technology in Haemapheresis (Proceedings), Paris: ESH 1997:1–8.
7. H. Results of an open, longitudinal multicenter LDL-apheresis trial. Transfusion Sci 2000; 20:83–94.
<https://doi.org/10.1016/S0955-3886(98)00097-6>
8. H, Gaczkowski A, Hombach V, Oette K, Stoffel W. Treatment of familial hypercholesterolemia by means of specific immunoadsorbtion. J Clin Apheresis 1988; 4:59–65.
<https://doi.org/10.1002/jca.2920040204>
9. T. Direct adsorption of lipoproteins from whole blood by DALI apheresis: technique and effects. Ther Apher 2001; 5:239–43.
<https://doi.org/10.1046/j.1526-0968.2001.00340.x>
10. N, Bosch, T. Immunoadsorption, current status and future developments. Expert Opinion Investig Drugs 2000; 9:2017–38.
<https://doi.org/10.1517/13543784.9.9.2017>
11. E. Efficacy of LDL-apheresis and the less specific technique which is plasmapheresis. Transfusion Sci 1999; 20:43–7.
<https://doi.org/10.1016/S0955-3886(98)00090-3>
12. JL, Tourraine R, Maunand B, Truffert J, Laudat P. Forms homozygotes cutanéo-tendineuses de xanthomatose hypercholestérolémique dans une observation familiale exemplaire. Essai de plasmaphérèse à titre de traitment héroique. Bull Mem Soc Hop Paris 1967; 118:1377–1402.
13. M.J. Plasmapheresis in the dysproteinemias. Ther Apher 2002; 6:45–52.
<https://doi.org/10.1046/j.1526-0968.2002.00393.x>
14. B. Plasmapheresis – principles and practice. J Indian Med Ass 2001; 99:364–67.
15. H, Michishita J, Mitsuaki T et al. A new low density lipoprotein apheresis system using two dextran sulphate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). Atherosclerosis 1987; 68: 19–25.
<https://doi.org/10.1016/0021-9150(87)90089-X>
16. S. Current topics pn immunoadsorption therapy. Ther Apher 1980; 5: 301–5.
<https://doi.org/10.1046/j.1526-0968.2001.00360.x>
17. R, Berséus O, Stegmayr B. Adverse events and problems in therapeutic hemapheresis. A report from the Swedish registry. Transfusion Apher Sci 2001; 25: 33–41.
<https://doi.org/10.1016/S1473-0502(01)00079-9>
18. Y, Usami M, Malchesky PS et al. Clinical thermofiltration: initial application. Artif Organs 1985; 9:425–7.
<https://doi.org/10.1111/j.1525-1594.1985.tb04406.x>
19. S. Current topics on centrifugal plasmapheresis technology. Ther Apher 2001; 5:264–9.
<https://doi.org/10.1046/j.1526-0968.2001.00356.x>
20. D, Armtsrong VW, Schuff-Werner P. The HELP-LDL-Apheresis Multicentre Study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. I. Evaluation of safety and cholesterol-lowering affects during the first 12 month. Eur J Clin Investig 1991; 21:375–83.
<https://doi.org/10.1111/j.1365-2362.1991.tb01384.x>
21. P, Holdt B. Selective hemapheresis, an effective new approach in the therapeutic management of disorders assotiated with rheumatological impairment: mode of action and possible clinical indications. Artif Org 2002; 6: 117–23.
<https://doi.org/10.1046/j.1525-1594.2002.06879.x>
22. WH, Borberg H, Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolemia. Lancet 1981; 2: 1005–7.
<https://doi.org/10.1016/S0140-6736(81)91213-7>
23. GR, Lowentahl R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1975; 2:1209–11.
24. H, Seidel D. A simple method for precipitation of low density lipoproteins. J Lipid Res 1983; 24:904.
25. A, Harada-Shiba M, Kawaguchi A, Tsushima M. Apheresis technology for prevention and regression of atherosclerosis. Ther Apher 2001; 5: 221–5.
<https://doi.org/10.1046/j.1526-0968.2001.00328.x>
